Boost for AZ as Ultomiris gets CHMP nod for expanded labelFresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion Share XBoost for AZ as Ultomiris gets CHMP nod for expanded labelhttps://pharmaphorum.com/news/boost-for-az-as-ultomiris-gets-chmp-nod-for-expanded-label/
NHS sets aside £340m for new Innovative Medicines FundNHS England has matched its financial backing of the Cancer Drugs Fund (CDF) with an equivalent pot of Share XNHS sets aside £340m for new Innovative Medicines Fundhttps://pharmaphorum.com/news/nhs-sets-aside-340m-for-new-innovative-medicines-fund/
Bluebird claims EU nod for rare disease therapy SkysonaBluebird bio has its first approval for Skysona (formerly Lenti-D), its gene therapy for children with the rare Share XBluebird claims EU nod for rare disease therapy Skysonahttps://pharmaphorum.com/news/bluebird-claims-eu-nod-for-rare-disease-therapy-skysona/
Final hurdle falls as UK backs AZ’s $39bn takeover of AlexionThe UK’s competition regulator has approved AstraZeneca’s $39 billion acquisition of US-based drugmaker Alexion, without opting for a Share XFinal hurdle falls as UK backs AZ’s $39bn takeover of Alexionhttps://pharmaphorum.com/news/final-hurdle-falls-as-uk-backs-azs-39bn-takeover-of-alexion/
Novo Nordisk bulks up in rare diseases with $1.2bn Prothena dealDiabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition Share XNovo Nordisk bulks up in rare diseases with $1.2bn Prothena dealhttps://pharmaphorum.com/news/novo-nordisk-bulks-up-in-rare-diseases-with-1-2bn-prothena-deal/
NICE rejects Orchard’s gene therapy for rare childhood disease MLDOrchard Therapeutics’ gene therapy for rare childhood disease metachromatic leukodystrophy (MLD) Libmeldy has been rejected for NHS use Share XNICE rejects Orchard’s gene therapy for rare childhood disease MLDhttps://pharmaphorum.com/news/nice-rejects-orchards-gene-therapy-for-rare-childhood-disease-mld/
MHRA grants bluebird ‘innovation passport’ for sickle cell therapybluebird bio’s sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an ‘innovation passport’ introduced Share XMHRA grants bluebird ‘innovation passport’ for sickle cell therapyhttps://pharmaphorum.com/news/mhra-grants-bluebird-innovation-passport-for-sickle-cell-therapy/
Intellia, Regeneron ace first trial with ‘in vivo’ CRISPR drugThe first ever clinical data with a CRISPR/Cas9 drug used to edit the genomes of cells within the Share XIntellia, Regeneron ace first trial with ‘in vivo’ CRISPR drughttps://pharmaphorum.com/news/intellia-regeneron-ace-first-trial-with-in-vivo-crispr-drug/
Biogen’s ambitions in gene therapy hit by another failed pivotal trialWhen Biogen acquired Nightstar Therapeutics in 2019, it added a pair inherited retinal disorder (IRD) gene therapies that Share XBiogen’s ambitions in gene therapy hit by another failed pivotal trialhttps://pharmaphorum.com/news/biogens-ambitions-in-gene-therapy-are-hit-by-a-second-failed-phase-3-trial/
